Ad-hoc | 20 March 2015 00:47
Evotec AG / Key word(s): Alliance
20.03.2015 00:47
Dissemination of an Ad hoc announcement according to ยง 15 WpHG, transmitted
by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Evotec and Sanofi sign definitive agreement for major multi-component
strategic alliance
Hamburg, Germany - Evotec AG (Frankfurt Stock Exchange, Prime Standard,
ISIN: DE 000 566480 9, WKN 566480) today announced the signing of a
definitive agreement for a major multi-component strategic alliance over
the next five years with Sanofi. The transaction is expected to close on 31
March 2015. The signing successfully concludes the exclusive negotiations
for a major multi-component strategic collaboration between the two
companies entered and announced on 02 December 2014.
The definitive agreement defines the conditions under which Evotec and
Sanofi intend to jointly progress a portfolio of primarily oncology related
projects, including five advanced, pre-clinical projects and further
discovery-stage assets, to IND ("Investigational New Drug") status or other
value inflection points before partnering them. Evotec and Sanofi will also
enter into an outsourcing alliance and Evotec will acquire Sanofi's
scientific operations in Toulouse, France. Evotec will integrate these
scientific operations including more than 200 highly experienced employees
into its global drug discovery platform. From this new facility, Evotec
will perform collaborative research with its Pharma, biotech and academic
partners as well as internal research. Evotec will also assume management
of Sanofi's global screening library and will combine its own and Sanofi's
compound libraries and make them available for screening projects to
Evotec's partners.
The collaboration will result in a minimum guaranteed commitment from
Sanofi to Evotec of EUR 250 m over the next five years, including more than
EUR 40 m upfront cash payment.
Contact: Dr Werner Lanthaler, Chief Executive Officer, Evotec AG, Manfred
Eigen Campus, Essener Bogen 7, 22419 Hamburg, Germany, Phone: +49.(0)40.560
81-242, werner.lanthaler@evotec.com
20.03.2015 The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Evotec AG
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Phone: +49 (0)40 560 81-0
Fax: +49 (0)40 560 81-222
E-mail: info@evotec.com
Internet: www.evotec.com
ISIN: DE0005664809
WKN: 566480
Indices: TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover,
Munich, Stuttgart
End of Announcement DGAP News-Service
---------------------------------------------------------------------------